NKGen Biotech, Inc.
Clinical trials sponsored by NKGen Biotech, Inc., explained in plain language.
Biotech developing natural killer cell therapies for cancer and neurodegenerative diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could your own immune cells fight Alzheimer's? new trial launches Results expected Dec 2026 (estimated)
-
Could your own immune cells fight Alzheimer's? new trial launches
Disease control Recruiting nowThis early-stage trial is testing whether a personalized natural killer (NK) cell therapy called SNK01 is safe and might help people with moderate Alzheimer's disease. The treatment is made from each patient's own immune cells and given as an IV infusion every three weeks for up …
Phase 1/2 • Sponsor: NKGen Biotech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could immune cells fight Alzheimer's? new study tests Long-Term safety
Disease control Recruiting nowThis study is testing the long-term safety of SNK01, a personalized therapy made from a patient's own natural killer cells, in 30 people with Alzheimer's disease. It is an extension of an earlier trial and aims to see if the treatment is safe and tolerable over time. Researchers …
Phase 2 • Sponsor: NKGen Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC